Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?

Carbone M, Yang H, Gaudino G.

J Thorac Oncol. 2019 Feb;14(2):157-159. doi: 10.1016/j.jtho.2018.11.006. Epub 2018 Dec 28. No abstract available.

2.

A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.

Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, Takinishi Y, Yamamoto R, Minaai M, Hashimoto-Tamaoki T, Ohmuraya M, Goto K, Goparaju C, Sarin KY, Tanji M, Bononi A, Napolitano A, Gaudino G, Hesdorffer M, Yang H, Carbone M.

J Clin Oncol. 2018 Oct 30:JCO2018790352. doi: 10.1200/JCO.2018.79.0352. [Epub ahead of print]

PMID:
30376426
3.

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Chen Z, Gaudino G, Pass HI, Carbone M, Yang H.

Transl Lung Cancer Res. 2017 Jun;6(3):259-269. doi: 10.21037/tlcr.2017.05.06. Review.

4.

Germline BAP1 mutations induce a Warburg effect.

Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, Xie G, Signorato V, Pastorino S, Morris P, Sakamoto G, Kuchay S, Gaudino G, Pass HI, Napolitano A, Pinton P, Jia W, Carbone M.

Cell Death Differ. 2017 Oct;24(10):1694-1704. doi: 10.1038/cdd.2017.95. Epub 2017 Jun 30.

5.

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M.

Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.

6.

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.

Szymiczek A, Pastorino S, Larson D, Tanji M, Pellegrini L, Xue J, Li S, Giorgi C, Pinton P, Takinishi Y, Pass HI, Furuya H, Gaudino G, Napolitano A, Carbone M, Yang H.

J Transl Med. 2017 Mar 15;15(1):58. doi: 10.1186/s12967-017-1158-z.

7.

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.

Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H.

Oncotarget. 2017 Apr 4;8(14):22649-22661. doi: 10.18632/oncotarget.15152.

8.

Possible Therapeutic Effects of Ozone Mixture on Hypoxia in Tumor Development.

Luongo M, Brigida AL, Mascolo L, Gaudino G.

Anticancer Res. 2017 Feb;37(2):425-435. Review.

PMID:
28179287
9.

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.

Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, Szymiczek A, Bononi A, Tanji M, Pagano I, Gaudino G, Napolitano A, Goparaju C, Pass HI, Yang H, Carbone M.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13432-13437. Epub 2016 Nov 9.

10.

Unbalanced Immune System: Immunodeficiencies and Autoimmunity.

Giardino G, Gallo V, Prencipe R, Gaudino G, Romano R, De Cataldis M, Lorello P, Palamaro L, Di Giacomo C, Capalbo D, Cirillo E, D'Assante R, Pignata C.

Front Pediatr. 2016 Oct 6;4:107. eCollection 2016. Review.

11.

Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s.

Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, Hoffman H, Hesdorffer M, Nasu M, Napolitano A, Powers A, Minaai M, Baumann F, Bryant-Greenwood P, Lauk O, Kirschner MB, Weder W, Opitz I, Pass HI, Gaudino G, Pastorino S, Yang H.

PLoS Genet. 2015 Dec 18;11(12):e1005633. doi: 10.1371/journal.pgen.1005633. eCollection 2015 Dec.

12.

Numerous Iron-Rich Particles Lie on the Surface of Erionite Fibers from Rome (Oregon, USA) and Karlik (Cappadocia, Turkey).

Croce A, Allegrina M, Rinaudo C, Gaudino G, Yang H, Carbone M.

Microsc Microanal. 2015 Oct;21(5):1341-7. doi: 10.1017/S1431927615014762. Epub 2015 Aug 19.

PMID:
26286705
13.

Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.

Yang H, Pellegrini L, Napolitano A, Giorgi C, Jube S, Preti A, Jennings CJ, De Marchis F, Flores EG, Larson D, Pagano I, Tanji M, Powers A, Kanodia S, Gaudino G, Pastorino S, Pass HI, Pinton P, Bianchi ME, Carbone M.

Cell Death Dis. 2015 Jun 11;6:e1786. doi: 10.1038/cddis.2015.153.

14.

Preclinical development of HIvax: Human survivin highly immunogenic vaccines.

Hoffmann PR, Panigada M, Soprana E, Terry F, Bandar IS, Napolitano A, Rose AH, Hoffmann FW, Ndhlovu LC, Belcaid M, Moise L, De Groot AS, Carbone M, Gaudino G, Matsui T, Siccardi A, Bertino P.

Hum Vaccin Immunother. 2015;11(7):1585-95. doi: 10.1080/21645515.2015.1050572.

15.

Recent insights emerging from malignant mesothelioma genome sequencing.

Carbone M, Gaudino G, Yang H.

J Thorac Oncol. 2015 Mar;10(3):409-11. doi: 10.1097/JTO.0000000000000466. No abstract available.

16.

High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.

Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, Becich MJ, Pass HI, Yang H, Carbone M.

J Thorac Oncol. 2015 Apr;10(4):565-76. doi: 10.1097/JTO.0000000000000471.

17.

Evaluation of clonal origin of malignant mesothelioma.

Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A, Baumann F, Weigel T, Friedberg J, Sugarbaker P, Krausz T, Wang E, Powers A, Gaudino G, Kanodia S, Pass HI, Parsons BL, Yang H, Carbone M.

J Transl Med. 2014 Dec 4;12:301. doi: 10.1186/s12967-014-0301-3.

18.

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis.

Gaudino G, Yang H, Carbone M.

Biomedicines. 2014 Nov 14;2(4):327-344. doi: 10.3390/biomedicines2040327. Review.

19.

The zeta potential of mineral fibres.

Pollastri S, Gualtieri AF, Gualtieri ML, Hanuskova M, Cavallo A, Gaudino G.

J Hazard Mater. 2014 Jul 15;276:469-79. doi: 10.1016/j.jhazmat.2014.05.060. Epub 2014 May 29.

PMID:
24929786
20.

Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors.

Rose AH, Bertino P, Hoffmann FW, Gaudino G, Carbone M, Hoffmann PR.

Am J Pathol. 2014 Apr;184(4):1041-1049. doi: 10.1016/j.ajpath.2013.12.008. Epub 2014 Feb 1.

21.

Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling.

Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, Demay RM, Khan G, Tiirikainen M, Rinaudo C, Croce A, Yang H, Gaudino G, Carbone M.

Am J Pathol. 2013 Nov;183(5):1654-66. doi: 10.1016/j.ajpath.2013.07.029.

22.

BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, Mutti L, Gunasekharan VK, Gorski JJ, El-Tanani M, Broaddus VC, Gaudino G, Fennell DA.

PLoS One. 2013 Jun 7;8(6):e65489. doi: 10.1371/journal.pone.0065489. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055. Barbone, Dario [added]; Mutti, Luciano [added].

23.

BAP1 and cancer.

Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G.

Nat Rev Cancer. 2013 Mar;13(3):153-9. doi: 10.1038/nrc3459.

24.

Fowlpox-based survivin vaccination for malignant mesothelioma therapy.

Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, Siccardi A, Carbone M.

Int J Cancer. 2013 Aug 1;133(3):612-23. doi: 10.1002/ijc.28048. Epub 2013 Feb 25.

25.

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.

Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, Hyjek E, Tate R, Friedberg J, Weigel T, Pass HI, Yang H.

J Transl Med. 2012 Aug 30;10:179. doi: 10.1186/1479-5876-10-179.

26.

CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.

Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M.

Clin Cancer Res. 2012 Oct 1;18(19):5352-63. doi: 10.1158/1078-0432.CCR-12-0628. Epub 2012 Aug 14.

27.

Reducing self-control by weakening belief in free will.

Rigoni D, Kühn S, Gaudino G, Sartori G, Brass M.

Conscious Cogn. 2012 Sep;21(3):1482-90. doi: 10.1016/j.concog.2012.04.004. Epub 2012 May 9.

PMID:
22579497
28.

Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.

Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H.

Cancer Res. 2012 Jul 1;72(13):3290-301. doi: 10.1158/0008-5472.CAN-11-3481. Epub 2012 May 2.

29.

Simian virus 40 transformation, malignant mesothelioma and brain tumors.

Qi F, Carbone M, Yang H, Gaudino G.

Expert Rev Respir Med. 2011 Oct;5(5):683-97. doi: 10.1586/ers.11.51. Review.

30.

Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth.

Nasu M, Carbone M, Gaudino G, Ly BH, Bertino P, Shimizu D, Morris P, Pass HI, Yang H.

Genes Cancer. 2011 May;2(5):576-84. doi: 10.1177/1947601911412375.

31.

Germline BAP1 mutations predispose to malignant mesothelioma.

Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M.

Nat Genet. 2011 Aug 28;43(10):1022-5. doi: 10.1038/ng.912.

32.

Erionite exposure in North Dakota and Turkish villages with mesothelioma.

Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, Gaudino G, Jube S, Kanodia S, Partridge CR, Pass HI, Rivera ZS, Steele I, Tuncer M, Way S, Yang H, Miller A.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13618-23. doi: 10.1073/pnas.1105887108. Epub 2011 Jul 25.

33.

Tissue Tropism of SV40 Transformation of Human Cells: Role of the Viral Regulatory Region and of Cellular Oncogenes.

Zhang L, Qi F, Gaudino G, Strianese O, Yang H, Morris P, Pass HI, Nerurkar VR, Bocchetta M, Carbone M.

Genes Cancer. 2010 Oct;1(10):1008-20. doi: 10.1177/1947601910395580.

34.

MicroRNA regulation of core apoptosis pathways in cancer.

Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH.

Eur J Cancer. 2011 Jan;47(2):163-74. doi: 10.1016/j.ejca.2010.11.005. Epub 2010 Dec 8. Review.

PMID:
21145728
35.

Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.

Favoni RE, Pattarozzi A, Lo Casto M, Barbieri F, Gatti M, Paleari L, Bajetto A, Porcile C, Gaudino G, Mutti L, Corte G, Florio T.

Curr Cancer Drug Targets. 2010 Mar;10(2):176-91.

PMID:
20088784
36.

Malignant pleural mesothelioma: current treatments and emerging drugs.

Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L.

Expert Opin Emerg Drugs. 2009 Sep;14(3):423-37. doi: 10.1517/14728210903074563. Review.

PMID:
19552609
37.

MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.

Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G.

Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9. doi: 10.1165/rcmb.2009-0060OC. Epub 2009 Jun 5.

PMID:
19502386
38.

RNF168, a new RING finger, MIU-containing protein that modifies chromatin by ubiquitination of histones H2A and H2AX.

Pinato S, Scandiuzzi C, Arnaudo N, Citterio E, Gaudino G, Penengo L.

BMC Mol Biol. 2009 Jun 5;10:55. doi: 10.1186/1471-2199-10-55.

39.

Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.

Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L.

Cancer Res. 2009 Jun 1;69(11):4598-604. doi: 10.1158/0008-5472.CAN-08-4523.

40.

Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.

Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G.

Eur Respir J. 2009 Dec;34(6):1399-407. doi: 10.1183/09031936.00102308. Epub 2009 May 21.

41.

Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma.

Catassi A, Paleari L, Servent D, Sessa F, Dominioni L, Ognio E, Cilli M, Vacca P, Mingari M, Gaudino G, Bertino P, Paolucci M, Calcaterra A, Cesario A, Granone P, Costa R, Ciarlo M, Alama A, Russo P.

Eur J Cancer. 2008 Oct;44(15):2296-311. doi: 10.1016/j.ejca.2008.06.045. Epub 2008 Aug 20.

PMID:
18722110
42.

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.

Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC.

J Biol Chem. 2008 May 9;283(19):13021-30. doi: 10.1074/jbc.M709698200. Epub 2008 Mar 13.

43.

Advances in the systemic therapy of malignant pleural mesothelioma.

Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J.

Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. Review.

PMID:
18227828
44.

Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.

Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, Mutti L, Gaudino G.

Clin Cancer Res. 2008 Jan 15;14(2):541-8. doi: 10.1158/1078-0432.CCR-07-1388.

45.

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.

Clin Cancer Res. 2007 Oct 1;13(19):5942-51. Erratum in: Clin Cancer Res. 2007 Nov 1;13(21):6543.

46.

Erionite and asbestos differently cause transformation of human mesothelial cells.

Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S, Dogan AU, Tassi GF, Porta C, Mutti L, Gaudino G.

Int J Cancer. 2007 Jul 1;121(1):12-20.

47.

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, Mutti L.

Thorax. 2007 Aug;62(8):690-5. Epub 2007 Feb 20.

48.

Alpha- and betapapillomavirus E6/E7 genes differentially modulate pro-inflammatory gene expression.

De Andrea M, Mondini M, Azzimonti B, Dell'Oste V, Germano S, Gaudino G, Musso T, Landolfo S, Gariglio M.

Virus Res. 2007 Mar;124(1-2):220-5. Epub 2006 Oct 31.

PMID:
17079045
49.

Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling.

Germano S, Barberis D, Santoro MM, Penengo L, Citri A, Yarden Y, Gaudino G.

J Biol Chem. 2006 Aug 4;281(31):21710-9. Epub 2006 Jun 1.

50.

Supplemental Content

Loading ...
Support Center